Magali Legarff-Tavernier, MD

INSERM, UMR-S 945, AP-HP, Hôpital Pitié-Salpêtrière, Service d'Hématologie Biologique
Paris, France

NA

Presentation(s):

• (1547411) Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk : interim results of MRD kinetics in the ERADIC trial from the FILO group

  Sunday, October 8, 2023
  9:25 AM – 9:35 AM EDT